| 0.455 0.001 (0.22%) | 04-27 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.54 | 1-year : | 0.63 |
| Resists | First : | 0.46 | Second : | 0.54 |
| Pivot price | 0.44 |
|||
| Supports | First : | 0.38 | Second : | 0.33 |
| MAs | MA(5) : | 0.45 |
MA(20) : | 0.44 |
| MA(100) : | 0.37 |
MA(250) : | 0 | |
| MACD | MACD : | 0  |
Signal : | 0 |
| %K %D | K(14,3) : | 71.7 |
D(3) : | 67.8 |
| RSI | RSI(14): 58 |
|||
| 52-week | High : | 1.24 | Low : | 0.18 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CEMI ] has closed below upper band by 31.7%. Bollinger Bands are 74.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.46 - 0.46 | 0.46 - 0.46 |
| Low: | 0.45 - 0.45 | 0.45 - 0.45 |
| Close: | 0.45 - 0.45 | 0.45 - 0.46 |
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as sells its products directly through distributors to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.
Thu, 02 May 2024
Do Insiders Own Shares In Chembio Diagnostics, Inc. (NASDAQ:CEMI)? - Yahoo Movies Canada
Mon, 10 Apr 2023
Chembio Stockholders Reminded to Tender Shares Before 6:00 P.M., New York City Time, on April 12, 2023 - Yahoo Finance
Wed, 01 Feb 2023
French Rapid Testing Company Scoops Up Chembio Diagnostics For $17M - Yahoo Finance
Wed, 01 Feb 2023
White & Case Advises Biosynex on Merger Agreement With Chembio Diagnostics, Inc. - White & Case LLP
Tue, 31 Jan 2023
Biosynex and Chembio Diagnostics Announce Definitive Acquisition Agreement - GlobeNewswire
Tue, 06 Apr 2021
CEMI Stock News: Chembio Diagnostics Inc skyrockets 60% after FDA greenlights rapid covid/flu tests - FXStreet
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 37 (M) |
| Shares Float | 31 (M) |
| Held by Insiders | 2.3 (%) |
| Held by Institutions | 21.6 (%) |
| Shares Short | 292 (K) |
| Shares Short P.Month | 327 (K) |
| EPS | -0.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.49 |
| Profit Margin | -47.1 % |
| Operating Margin | -41.3 % |
| Return on Assets (ttm) | -18.8 % |
| Return on Equity (ttm) | -89.5 % |
| Qtrly Rev. Growth | -49.8 % |
| Gross Profit (p.s.) | 0.1 |
| Sales Per Share | 1.34 |
| EBITDA (p.s.) | -0.49 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -13 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.64 |
| PEG Ratio | 0 |
| Price to Book value | 0.92 |
| Price to Sales | 0.33 |
| Price to Cash Flow | -1.32 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|